Serodiagnosis_NN of_IN Imported_NP Schistosomiasis_NP by_IN a_DT Combination_NN of_IN a_DT Commercial_JJ Indirect_NN Hemagglutination_NP Test_NP with_IN Schistosoma_NP mansoni_NP Adult_NP Worm_NP Antigens_NNS and_CC an_DT Enzyme-Linked_NP Immunosorbent_NP Assay_NP with_IN S._NP mansoni_NP Egg_NP Antigens_VBZ A_DT commercial_JJ indirect_JJ hemagglutination_NN (_( IHA_NP )_) test_NN using_VBG erythrocytes_NNS coated_VBN with_IN Schistosoma_NP mansoni_NP adult_NN worm_NN antigens_NNS (_( WA_NP )_) and_CC an_DT enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) with_IN S._NP mansoni_NP egg_NN antigens_NNS (_( SEA_NP )_) were_VBD assessed_VBN for_IN their_PP$ use_NN in_IN serodiagnosis_NN of_IN imported_VBN schistosomiasis_NN (_( hereafter_RB these_DT tests_NNS are_VBP designated_VBN WA/IHA_NP and_CC SEA/ELISA_NP ,_, respectively_RB )_) ._SENT The_DT sensitivity_NN of_IN the_DT tests_NNS was_VBD evaluated_VBN with_IN sera_NN from_IN 75_CD patients_NNS with_IN proven_JJ S._NP mansoni_NN infection_NN ,_, 25_CD with_IN proven_JJ S._NP haematobium_NN infection_NN ,_, and_CC 10_CD with_IN clinical_JJ Katayama_NP fever_NN ._SENT The_DT specificity_NN was_VBD assessed_VBN with_IN sera_NN from_IN 283_CD patients_NNS with_IN various_JJ parasitic_JJ ,_, bacterial_JJ ,_, viral_JJ ,_, and_CC fungal_JJ infections_NNS and_CC sera_NN containing_VBG autoimmune_JJ antibodies_NNS ._SENT Sensitivities_NNS of_IN the_DT WA/IHA_NP with_IN a_DT cutoff_NN titer_NN of_IN 1:160_CD (_( WA/IHA160_NP )_) in_IN detecting_VBG S._NP mansoni_NP ,_, S._NP haematobium_NN ,_, S._NP mansoni_NP and_CC S._NP haematobium_NN combined_VBN ,_, and_CC clinical_JJ Katayama_NP fever_NN were_VBD 88.0_CD ,_, 80.0_CD ,_, 86.0_CD ,_, and_CC 70.0_CD %_NN ,_, respectively_RB ,_, with_IN a_DT specificity_NN of_IN 98.9_CD %_NN ._SENT The_DT WA/IHA_NP with_IN a_DT cutoff_NN of_IN 1:80_CD (_( WA/IHA80_NP )_) showed_VBD sensitivities_NNS of_IN 94.7_CD ,_, 92.0_CD ,_, 94.0_CD ,_, and_CC 90.0_CD %_NN ,_, respectively_RB ,_, with_IN a_DT specificity_NN of_IN 94.7_CD %_NN ._SENT The_DT comparable_JJ values_NNS of_IN SEA/ELISA_NP were_VBD 93.3_CD ,_, 92.0_CD ,_, 93.0_CD ,_, and_CC 50.0_CD %_NN ,_, respectively_RB ,_, with_IN a_DT specificity_NN of_IN 98.2_CD %_NN ._SENT Combined_JJ use_NN of_IN ELISA_NP and_CC WA/IHA80_NP gave_VBD sensitivities_NNS of_IN 100_CD %_NN for_IN S._NP mansoni_NP ,_, S._NP haematobium_NN ,_, and_CC S._NP mansoni_NP and_CC S._NP haematobium_NN combined_VBN and_CC 90_CD %_NN for_IN Katayama_NP fever_NN ._SENT The_DT specificity_NN of_IN this_DT combination_NN in_IN detecting_VBG schistosomiasis_NN was_VBD 92.9_CD %_NN ._SENT Combination_NN of_IN SEA/ELISA_NP with_IN WA/IHA160_NP gave_VBD sensitivities_NNS of_IN 98.7_CD ,_, 96.0_CD ,_, 98.0_CD ,_, and_CC 80_CD %_NN with_IN a_DT specificity_NN of_IN 97.2_CD %_NN ._SENT Our_PP$ findings_NNS suggest_VBP that_IN WA/IHA_NP and_CC SEA/ELISA_NP are_VBP each_DT sensitive_JJ and_CC specific_JJ serological_JJ tests_NNS that_WDT are_VBP easy_JJ to_TO use_VB for_IN the_DT diagnosis_NN of_IN imported_VBN schistosomiasis_NN ._SENT The_DT combined_JJ use_NN of_IN these_DT two_CD tests_NNS enabled_VBD the_DT serological_JJ diagnosis_NN of_IN schistosomiasis_NN to_TO be_VB achieved_VBN with_IN very_RB high_JJ degrees_NNS of_IN both_DT sensitivity_NN and_CC specificity_NN ._SENT Schistosomiasis_NN is_VBZ a_DT major_JJ cause_NN of_IN morbidity_NN and_CC mortality_NN and_CC has_VBZ been_VBN estimated_VBN to_TO infect_VB over_IN 200_CD million_CD people_NNS ._SENT An_DT estimated_VBD 500-_CD to_TO 600_CD million_CD people_NNS worldwide_RB are_VBP still_RB at_IN risk_NN of_IN infection_NN ._SENT The_DT disease_NN occurs_VBZ mostly_RB in_IN the_DT tropical_JJ regions_NNS ,_, particularly_RB in_IN Africa_NP ,_, South_NP America_NP ,_, and_CC the_DT Far_NP East_NP ,_, and_CC is_VBZ endemic_JJ in_IN 74_CD developing_VBG nations_NNS ._SENT Schistosomiasis_NN is_VBZ frequently_RB imported_VBN into_IN nonendemic_JJ areas_NNS by_IN immigrants_NNS and_CC travelers_NNS returning_VBG from_IN the_DT tropics_NNS ._SENT Cases_NNS of_IN imported_VBN schistosomiasis_NN are_VBP on_IN the_DT increase_NN due_JJ to_TO changes_NNS in_IN travel_NN destinations_NNS and_CC habits_NNS of_IN travelers_NNS while_IN abroad_RB ._SENT Most_JJS of_IN these_DT patients_NNS are_VBP asymptomatic_JJ ,_, but_CC recent_JJ infection_NN can_MD cause_VB serious_JJ disease_NN ,_, such_JJ as_IN Katayama_NP fever_NN or_CC severe_JJ neurological_JJ complications_NNS involving_VBG the_DT spinal_JJ cord_NN ._SENT Diagnosis_NN of_IN schistosomiasis_NN by_IN detection_NN of_IN specific_JJ antibodies_NNS is_VBZ likely_JJ to_TO be_VB more_RBR sensitive_JJ than_IN the_DT traditional_JJ method_NN of_IN diagnosis_NN by_IN detection_NN of_IN eggs_NNS in_IN stool_NN or_CC urine_NN ._SENT In_IN imported_VBN infections_NNS ,_, with_IN only_RB a_DT few_JJ or_CC no_DT eggs_NNS being_VBG excreted_VBN ,_, antibody_NN detection_NN may_MD be_VB the_DT only_RB means_VBZ to_TO diagnose_VB schistosomiasis_JJ ._SENT In_IN order_NN to_TO incorporate_VB serodiagnostics_NNS in_IN routine_JJ clinical_JJ laboratory_NN practice_NN ,_, an_DT easy_JJ to_TO use_VB ,_, sensitive_JJ ,_, and_CC specific_JJ serological_JJ test_NN is_VBZ needed_VBN ._SENT Unfortunately_RB only_RB a_DT few_JJ serological_JJ tests_NNS for_IN schistosomiasis_NN are_VBP commercially_RB available_JJ ,_, and_CC still_RB fewer_JJR have_VBP been_VBN evaluated_VBN for_IN their_PP$ diagnostic_JJ use_NN ._SENT These_DT and_CC other_JJ difficulties_NNS (_( e.g._FW ,_, those_DT inherent_JJ in_IN antigen_NN preparation_NN for_IN such_JJ tests_NNS )_) tend_VBP to_TO restrict_VB serodiagnosis_NN in_IN general_NN to_TO larger_JJR research_NN centers_NNS ._SENT Serological_JJ tests_NNS which_WDT could_MD ,_, however_RB ,_, be_VB used_VBN in_IN routine_JJ clinical_JJ laboratories_NNS are_VBP an_DT indirect_JJ hemagglutination_NN (_( IHA_NP )_) assay_NN with_IN adult_JJ Schistosoma_NP mansoni_NN worm_NN antigens_NNS (_( WA_NP )_) produced_VBD by_IN Fumouze_NP Laboratories_NPS (_( Levallois-Perret_NP ,_, France_NP )_) (_( hereafter_RB this_DT assay_NN is_VBZ referred_VBN to_TO as_IN WA/IHA_NP )_) and_CC an_DT enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) with_IN S._NP mansoni_NP soluble_JJ egg_NN antigens_NNS (_( SEA_NP )_) (_( hereafter_RB referred_VBN to_TO as_IN SEA/ELISA_NP )_) ._SENT In_IN this_DT study_NN we_PP evaluated_VBD the_DT results_NNS obtained_VBN with_IN WA/IHA_NP and_CC SEA/ELISA_NP and_CC the_DT combined_JJ results_NNS of_IN both_DT tests_NNS for_IN their_PP$ sensitivity_NN and_CC specificity_NN for_IN patients_NNS returning_VBG from_IN the_DT tropics_NNS with_IN egg-positive_JJ S._NP mansoni_NP and_CC S._NP haematobium_NN infections_NNS and_CC individuals_NNS presenting_VBG at_IN the_DT clinic_NN with_IN Katayama_NP fever_NN ._SENT The_DT specificity_NN of_IN the_DT test_NN was_VBD evaluated_VBN with_IN patients_NNS with_IN various_JJ other_JJ infections_NNS and_CC autoimmune_JJ disorders_NNS ._SENT Patients_NNS and_CC sera_NN ._SENT |_SYM Patients_NNS incorporated_VBN into_IN this_DT study_NN attended_VBD The_DT Academic_NP Medical_NP Centre_NP ,_, Amsterdam_NP ,_, The_DT Netherlands_NPS ;_: The_DT Harbor_NP Hospital_NP and_CC Institute_NP of_IN Tropical_NP Diseases_NPS ,_, Rotterdam_NP ,_, The_DT Netherlands_NPS ;_: and_CC The_DT Prince_NP Leopold_NP Institute_NP of_IN Tropical_NP Medicine_NP ,_, Antwerp_NP ,_, Belgium_NP ._SENT A_DT total_NN of_IN 393_CD patients_NNS with_IN the_DT following_VBG characteristics_NNS were_VBD used_VBN ._SENT (_( i_NP )_) One_CD hundred_CD patients_NNS had_VBD egg-proven_NN schistosomiasis_NN (_( 75_CD patients_NNS with_IN S._NP mansoni_NP and_CC 25_CD patients_NNS with_IN S._NP haematobium_NN )_) ._SENT (_( ii_NN )_) Ten_CD patients_NNS had_VBD Katayama_NP fever_NN ._SENT All_DT patients_NNS had_VBD recently_RB visited_VBN a_DT schistosoma-endemic_JJ African_JJ country_NN ._SENT Patients_NNS presented_VBN with_IN eosinophilia_NN ,_, fever_NN ,_, symptoms_NNS of_IN myalgia_NN ,_, arthralgia_NN ,_, persistent_JJ dry_JJ cough_NN ,_, weight_NN loss_NN ,_, or_CC general_JJ malaise_NN ._SENT In_IN two_CD cases_NNS S._NP mansoni_NP eggs_NNS were_VBD observed_VBN in_IN stool_NN samples_NNS ._SENT (_( iii_NP )_) Two_NP hundred-forty_NN patients_NNS had_VBD other_JJ infectious_JJ diseases_NNS ._SENT All_DT patients_NNS had_VBD proven_VBN active_JJ infections_NNS or_CC were_VBD recently_RB infected_VBN ._SENT Included_VBN were_VBD patients_NNS with_IN fascioliasis_NN hepatica_NN (_( 3_CD )_) ,_, hookworm_NN infection_NN (_( 10_CD )_) ,_, trichuriasis_NN (_( 16_CD )_) ,_, strongyloidiasis_NN (_( 11_CD )_) ,_, filariasis_NN bancrofti_NNS (_( 24_CD )_) ,_, onchocerciasis_NN (_( 12_CD )_) ,_, loiasis_NN (_( 10_CD )_) ,_, hepatic_JJ amoebiasis_NN (_( 7_CD )_) ,_, visceral_JJ leishmaniasis_NN (_( 5_CD )_) ,_, malaria_NN (_( 9_CD )_) ,_, toxoplasmosis_NN (_( 11_CD )_) ,_, syphilis_NN (_( 8_CD )_) ,_, borreliosis_NN (_( 9_CD )_) ,_, human_JJ immunodeficiency_NN virus_NN infection_NN (_( 11_CD )_) ,_, cytomegalovirus_NN infection_NN (_( 12_CD )_) ,_, Epstein-Barr_NP infection_NN (_( 12_CD )_) ,_, hepatitis_NP A_NP (_( 22_CD )_) ,_, hepatitis_NP B_NP (_( 13_CD )_) ,_, rubella_NN (_( 11_CD )_) ,_, Coxsackie_NP B_NP virus_NN infection_NN (_( 11_CD )_) ,_, and_CC aspergillosis_NN (_( 11_CD )_) ._SENT (_( iv_NP )_) Twenty-three_NP patients_NNS had_VBD autoimmune_JJ antibodies_NNS (_( 12_CD patients_NNS with_IN rheumatoid_JJ factor_NN and_CC 11_CD with_IN anti-nuclear_JJ antibodies_NNS )_) ._SENT (_( v_NN )_) Twenty_NP patients_NNS were_VBD healthy_JJ blood_NN donors_NNS originating_VBG from_IN The_DT Netherlands_NPS ._SENT WA/IHA_NP ._SENT |_SYM The_DT IHA_NP test_NN kit_NN sold_VBN by_IN Fumouze_NP Laboratories_NPS was_VBD used_VBN according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS ,_, with_IN a_DT modification_NN that_IN the_DT U-shaped_JJ plates_NNS provided_VBN by_IN the_DT manufacturer_NN were_VBD replaced_VBN with_IN V-shaped_JJ microtiter_NN plates_NNS (_( Greiner_NP Laboratories_NP ,_, Alphen_NP ,_, The_DT Netherlands_NPS )_) ,_, as_IN the_DT latter_NN allowed_VBD better_JJR readability_NN of_IN the_DT results_NNS ._SENT Absence_NN of_IN agglutination_NN was_VBD observed_VBN with_IN the_DT V-shaped_JJ well_NN as_IN a_DT clear_JJ ,_, sharp_JJ dark_JJ spot_NN instead_RB of_IN the_DT more_JJR or_CC less_JJR wide_JJ ring_NN seen_VBN with_IN the_DT original_JJ U-shaped_JJ well_NN ._SENT Briefly_RB ,_, the_DT test_NN procedure_NN was_VBD as_RB follows_VBZ ._SENT Fifty_CD microliters_NNS of_IN a_DT 1:20_CD initial_JJ dilution_NN of_IN each_DT serum_NN was_VBD subjected_VBN to_TO further_VB twofold_JJ serial_JJ dilutions_NNS ,_, and_CC 10_CD mul_NN of_IN sheep_NN red_JJ blood_NN cells_NNS sensitized_VBN with_IN S._NP mansoni_NP adult_NN WA_NP was_VBD added_VBN to_TO each_DT diluted_JJ sample_NN ._SENT Positive_JJ and_CC negative_JJ control_NN sera_NN and_CC nonsensitized_JJ red_JJ blood_NN cells_NNS were_VBD included_VBN in_IN each_DT test_NN as_IN controls_NNS for_IN naturally_RB occurring_VBG antibodies_NNS ._SENT After_IN incubation_NN for_IN 2_CD h_NN at_IN room_NN temperature_NN the_DT titer_NN in_IN the_DT test_NN serum_NN was_VBD recorded_VBN as_IN one_CD dilution_NN before_IN that_DT which_WDT yielded_VBD a_DT clear_JJ ,_, sharp_JJ dark_JJ spot_NN similar_JJ to_TO those_DT in_IN the_DT negative_JJ control_NN wells_NNS ._SENT Titers_NNS were_VBD expressed_VBN as_IN reciprocal_JJ values_NNS ._SENT All_DT sera_NN were_VBD tested_VBN in_IN duplicate_NN ._SENT The_DT results_NNS were_VBD evaluated_VBN with_IN a_DT cutoff_NN titer_NN of_IN 1:160_CD as_RB recommended_VBN by_IN the_DT manufacturer_NN and_CC also_RB with_IN a_DT cutoff_NN of_IN 1:80_CD ._SENT SEA/ELISA_NP ._SENT |_SYM SEA_NP was_VBD prepared_VBN by_IN retrieving_VBG eggs_NNS from_IN the_DT tissues_NNS of_IN mice_NNS heavily_RB infected_VBN with_IN an_DT S._NP mansoni_NN isolate_NN from_IN Puerto_NP Rico_NP ._SENT The_DT origin_NN of_IN the_DT parasites_NNS ,_, details_NNS of_IN their_PP$ laboratory_NN maintenance_NN ,_, and_CC methods_NNS for_IN isolation_NN of_IN eggs_NNS have_VBP been_VBN described_VBN previously_RB ._SENT The_DT eggs_NNS were_VBD homogenized_VBN by_IN disrupting_VBG them_PP for_IN 3_CD min_NN in_IN an_DT ice-cooled_JJ glass_NN homogenizer_NN with_IN a_DT mechanically_RB rotated_VBN Teflon_NP plunger_NN and_CC were_VBD centrifuged_VBN at_IN 20,000_CD x_NN g_NN for_IN 3_CD h_NN ,_, and_CC the_DT supernatant_JJ was_VBD used_VBN as_IN the_DT antigen_NN in_IN the_DT ELISA_NP ._SENT The_DT ELISA_NP for_IN detection_NN of_IN serum_NN immunoglobulin_NN G_NP against_IN SEA_NP was_VBD performed_VBN as_IN described_VBN previously_RB ,_, the_DT concentrations_NNS of_IN antigen_NN and_CC the_DT dilution_NN of_IN serum_NN samples_NNS and_CC anti-human_NN immunoglobulin_NN G_NN peroxidase_NN conjugate_VB having_VBG been_VBN determined_VBN by_IN checkerboard_NN titration_NN ._SENT However_RB ,_, polystyrene_NN high-binding_NN and_CC flat-bottom_NN enzyme_NN immunoassay/radioimmunoassay_NN plates_NNS (_( Costar_NP ,_, Corning_NP ,_, N.Y._NP )_) with_IN small_JJ wells_NNS were_VBD used_VBN ._SENT The_DT reaction_NN volume_NN of_IN each_DT reagent_NN at_IN each_DT step_NN in_IN these_DT plates_NNS was_VBD 30_CD mul_NN per_IN well_RB ._SENT Wells_NP were_VBD sensitized_VBN with_IN SEA_NP to_TO make_VB a_DT concentration_NN of_IN 1.3_CD mug/ml_NN with_IN 0.05_CD M_NP carbonate-bicarbonate_JJ buffer_NN ,_, pH_NN 9.6_CD ._SENT The_DT sensitization_NN was_VBD performed_VBN overnight_RB at_IN 4C_JJ ._SENT After_IN removal_NN of_IN the_DT unbound_JJ antigen_NN ,_, the_DT wells_NNS were_VBD treated_VBN with_IN 1_CD %_NN chicken_NN egg_NN white_JJ in_IN phosphate-buffered_JJ saline_NN (_( PBS_NP )_) at_IN 37C_JJ for_IN 30_CD min_NN ._SENT Wells_NP were_VBD washed_VBN five_CD times_NNS with_IN 0.05_CD %_NN Tween_NP 20_CD in_IN PBS_NP ,_, and_CC serum_NN samples_NNS (_( 1:400_CD dilution_NN )_) were_VBD added_VBN to_TO the_DT wells_NNS and_CC incubated_VBN for_IN 30_CD min_NN at_IN 37C_JJ ._SENT Each_DT serum_NN was_VBD tested_VBN in_IN duplicate_NN ._SENT After_IN washing_VBG the_DT wells_NNS five_CD times_NNS they_PP were_VBD filled_VBN with_IN a_DT 1:1,500_CD dilution_NN of_IN horseradish_NN peroxidase-conjugated_JJ goat_NN antibody_NN to_TO human_JJ immunoglobulin_NN G_NP (_( Nordic_NN ,_, Tilburg_NP ,_, The_DT Netherlands_NPS )_) ._SENT Following_VBG incubation_NN for_IN 30_CD min_NN at_IN 37C_JJ the_DT wells_NNS were_VBD washed_VBN three_CD times_NNS and_CC substrate_NN solution_NN (_( 0.01_CD %_NN 5-amino-2-salicyclic_JJ acid_NN in_IN phosphate_NN buffer_NN ,_, pH_NN 5.95_CD ,_, with_IN 0.03_CD %_NN H2O2_NP )_) was_VBD applied_VBN to_TO the_DT wells_NNS for_IN 1_CD h_NN in_IN the_DT dark_NN at_IN room_NN temperature_NN ._SENT The_DT optical_JJ density_NN (_( OD_NN )_) at_IN 492_CD nm_NN was_VBD read_VBN in_IN an_DT ELISA_NP reader_NN designed_VBN by_IN Labsystems_NP (_( Helsinki_NP ,_, Finland_NP )_) ._SENT To_TO correct_VB for_IN day-to-day_JJ assay_NN variation_NN the_DT results_NNS were_VBD expressed_VBN as_IN ratios_NNS between_IN the_DT absorbance_NN value_NN of_IN the_DT sample_NN and_CC that_IN of_IN a_DT well-defined_JJ control_NN serum_NN ._SENT The_DT cutoff_NN value_NN of_IN 0.222_CD was_VBD defined_VBN as_IN the_DT mean_JJ OD_NN plus_CC two_CD standard_JJ deviations_NNS of_IN the_DT serum_NN samples_NNS from_IN the_DT 283_CD controls_NNS (_( 240_CD patients_NNS with_IN other_JJ infectious_JJ diseases_NNS ,_, 23_CD with_IN autoantibodies_NNS ,_, and_CC 20_CD healthy_JJ Dutch_JJ blood_NN donors_NNS )_) ._SENT Definitions_NNS ._SENT |_SYM The_NP WA/IHA_NP was_VBD considered_VBN positive_JJ if_IN the_DT titer_NN of_IN the_DT serum_NN was_VBD equal_JJ to_TO or_CC greater_JJR than_IN the_DT cutoff_NN titers_NNS of_IN 1:80_CD or_CC 1:160_CD ._SENT The_DT SEA/ELISA_NP was_VBD considered_VBN positive_JJ if_IN the_DT OD_JJ value_NN of_IN the_DT serum_NN was_VBD equal_JJ to_TO or_CC greater_JJR than_IN the_DT cutoff_NN OD_NN of_IN 0.222_CD ._SENT The_DT combination_NN of_IN both_DT tests_NNS was_VBD deemed_VBN positive_JJ if_IN either_DT one_CD or_CC both_DT of_IN the_DT tests_NNS gave_VBD a_DT positive_JJ reaction_NN ._SENT Negative_JJ reactions_NNS in_IN WA/IHA_NP and_CC SEA/ELISA_NP showed_VBD lesser_JJR values_NNS than_IN the_DT cutoff_NN values_NNS ._SENT A_DT sample_NN was_VBD considered_VBN negative_JJ if_IN both_DT tests_NNS had_VBD given_VBN negative_JJ reactions_NNS ._SENT The_DT sensitivity_NN of_IN the_DT WA/IHA_NP ,_, the_DT SEA/ELISA_NP ,_, and_CC of_IN the_DT combination_NN of_IN both_DT tests_NNS was_VBD defined_VBN as_IN the_DT number_NN of_IN patients_NNS who_WP gave_VBD a_DT positive_JJ test_NN result_NN as_IN a_DT proportion_NN of_IN the_DT total_JJ number_NN of_IN patients_NNS who_WP had_VBD parasitologically_RB proven_VBN schistosomiasis_JJ or_CC clinical_JJ Katayama_NP fever_NN ._SENT The_DT specificity_NN of_IN the_DT tests_NNS and_CC of_IN the_DT combination_NN of_IN the_DT two_CD tests_NNS in_IN detecting_VBG schistosomiasis_NN was_VBD defined_VBN as_IN the_DT number_NN of_IN patients_NNS who_WP gave_VBD a_DT negative_JJ test_NN result_NN as_IN a_DT proportion_NN of_IN the_DT total_JJ number_NN of_IN control_NN patients_NNS (_( other_JJ infections_NNS ,_, autoimmune_JJ antibodies_NNS ,_, and_CC healthy_JJ Dutch_JJ blood_NN donors_NNS )_) ._SENT Sensitivities_NNS of_IN WA/IHA_NP ,_, SEA/ELISA_NP ,_, and_CC the_DT combination_NN of_IN both_DT tests_NNS in_IN detecting_VBG S._NP mansoni_NP ,_, S._NP haematobium_NN ,_, S._NP mansoni_NP and_CC S._NP haematobium_NN combined_VBN ,_, and_CC clinical_JJ Katayama_NP fever_NN and_CC the_DT specificities_NNS are_VBP shown_VBN in_IN Table_NP ._SENT Individual_JJ titers_NNS determined_VBN by_IN WA/IHA_NP and_CC OD_JJ values_NNS determined_VBN by_IN SEA/ELISA_NP from_IN schistosomiasis_JJ cases_NNS ,_, clinical_JJ Katayama_NP fever_NN cases_NNS ,_, and_CC control_NN cases_NNS are_VBP shown_VBN in_IN Fig._NN and_CC ,_, respectively_RB ._SENT Sensitivity_NN of_IN WA/IHA_NP with_IN a_DT cutoff_NN titer_NN of_IN 1:80_CD (_( WA/IHA80_NP )_) for_IN individuals_NNS excreting_VBG eggs_NNS of_IN S._NP mansoni_NP ,_, S._NP haematobium_NN ,_, both_CC infections_NNS combined_VBN ,_, and_CC with_IN clinical_JJ Katayama_NP fever_NN ranged_VBD from_IN 90.0_CD to_TO 94.7_CD %_NN ._SENT Sensitivity_NN of_IN WA/IHA_NP with_IN a_DT cutoff_NN titer_NN of_IN 1:160_CD (_( WA/IHA160_NP )_) for_IN detection_NN of_IN egg-positive_JJ cases_NNS and_CC cases_NNS with_IN clinical_JJ Katayama_NP fever_NN was_VBD lower_JJR and_CC ranged_VBD from_IN 70.0_CD to_TO 88.0_CD %_NN ._SENT WA/IHA_NP gave_VBD higher_JJR sensitivity_NN in_IN detecting_VBG S._NP mansoni_NP than_IN in_IN detecting_VBG S._NP haematobium_NN ._SENT The_DT specificity_NN in_IN detecting_VBG combined_JJ S._NP mansoni_NP and_CC S._NP haematobium_NN by_IN WA/IHA80_NP was_VBD 94.7_CD %_NN ._SENT Cross-reactive_JJ antibodies_NNS were_VBD observed_VBN in_IN some_DT of_IN the_DT putatively_RB negative_JJ control_NN sera_NN :_: most_RBS cross-reactive_JJ reactions_NNS had_VBD a_DT titer_NN of_IN 1:80_CD and_CC were_VBD observed_VBN in_IN the_DT filariasis_NN bancrofti_NN and_CC hepatitis_NN A_DT control_NN groups_NNS ._SENT However_RB ,_, with_IN a_DT dilution_NN of_IN 1:160_CD as_IN the_DT endpoint_NN in_IN WA/IHA_NP ,_, cross-reactive_JJ antibodies_NNS were_VBD rare_JJ and_CC WA/IHA160_NP had_VBD a_DT specificity_NN of_IN 98.9_CD %_NN ._SENT The_DT sensitivities_NNS of_IN SEA/ELISA_NP ranged_VBD from_IN 50.0_CD to_TO 93.3_CD %_NN ._SENT The_DT sensitivities_NNS in_IN detecting_VBG S._NP mansoni_NP and_CC S._NP haematobium_NN were_VBD comparable_JJ ._SENT Specificity_NN in_IN detecting_VBG schistosomiasis_NN was_VBD 98.2_CD %_NN ._SENT The_DT sensitivities_NNS of_IN the_DT results_NNS for_IN WA/IHA80_NP and_CC SEA/ELISA_NP combined_VBD ranged_VBN from_IN 90.0_CD to_TO 100_CD %_NN ,_, while_IN the_DT sensitivities_NNS for_IN the_DT WA/IHA160_NP and_CC SEA/ELISA_NP combination_NN were_VBD 80.0_CD to_TO 98.7_CD %_NN ._SENT The_DT combination_NN of_IN WA/IHA80_NP and_CC SEA/ELISA_NP gave_VBD a_DT specificity_NN of_IN 92.9_CD %_NN ,_, whereas_IN WA/IHA160_NP and_CC SEA/ELISA_NP combined_VBD had_VBD a_DT specificity_NN of_IN 97.2_CD %_NN ._SENT FIG._NN 1_CD ._SENT |_SYM Reciprocals_NP of_IN WA/IHA_NP titers_NNS in_IN sera_NN of_IN individuals_NNS with_IN S._NP mansoni_NP Reciprocals_NP of_IN WA/IHA_NP titers_NNS in_IN sera_NN of_IN individuals_NNS with_IN S._NP mansoni_NP (_( SMA_NP )_) ,_, S._NP haematobium_NP (_( SHA_NP )_) ,_, Katayama_NP fever_NN (_( KAT_NP )_) ,_, Fasciolia_NP hepatica_NN (_( FAS_NP )_) ,_, hookworm_NN infection_NN (_( HKW_NP )_) ,_, trichuriasis_NN (_( TRI_NP )_) ,_, strongyloidiasis_NN (_( STR_NP )_) ,_, filariasis_NN bancrofti_NNS (_( WUC_NP )_) ,_, loiasis_NN (_( LOA_NP )_) ,_, onchocerciasis_NN (_( ONC_NP )_) ,_, hepatic_JJ amoebiasis_NN (_( AMO_NP )_) ,_, malaria_NN (_( MAL_NP )_) ,_, visceral_JJ leishmaniasis_NN (_( VLE_NP )_) ,_, toxoplasmosis_NN (_( TOX_NP )_) ,_, syphilis_NN (_( SYP_NP )_) ,_, borreliosis_NN (_( BOR_NP )_) ,_, human_JJ immunodeficiency_NN virus_NN (_( HIV_NP )_) ,_, cytomegalovirus_NN (_( CMV_NP )_) ,_, Epstein-Barr_NP virus_NN (_( EBV_NP )_) ,_, hepatitis_NP A_NP (_( HEA_NP )_) ,_, hepatitis_NP B_NP (_( HEB_NP )_) ,_, rubella_NN (_( RUB_NP )_) ,_, aspergillosis_NN (_( ASP_NP )_) ,_, rheumatoid_JJ factor_NN (_( RHF_NP )_) ,_, anti-nuclear_JJ factor_NN (_( ANA_NP )_) ,_, and_CC Coxsackie_NP B_NP virus_NN (_( COB_NP )_) and_CC in_IN sera_NN of_IN healthy_JJ Dutch_JJ blood_NN donors_NNS (_( HEC_NP )_) ._SENT FIG._NN 2_CD ._SENT |_SYM OD_NN values_NNS at_IN 492_CD nm_NN by_IN SEA/ELISA_NP in_IN sera_NN of_IN individuals_NNS with_IN S._NP mansoni_NP OD_NP values_VBZ at_IN 492_CD nm_NN by_IN SEA/ELISA_NP in_IN sera_NN of_IN individuals_NNS with_IN S._NP mansoni_NP (_( SMA_NP )_) ,_, S._NP haematobium_NP (_( SHA_NP )_) ,_, Katayama_NP fever_NN (_( KAT_NP )_) ,_, fascioliasis_NN hepatica_NN (_( FAS_NP )_) ,_, hookworm_NN infection_NN (_( HKW_NP )_) ,_, trichuriasis_NN (_( TRI_NP )_) ,_, strongyloidiasis_NN (_( STR_NP )_) ,_, filariasis_NN bancrofti_NNS (_( WUC_NP )_) ,_, loiasis_NN (_( LOA_NP )_) ,_, onchocerciasis_NN (_( ONC_NP )_) ,_, hepatic_JJ amoebiasis_NN (_( AMO_NP )_) ,_, malaria_NN (_( MAL_NP )_) ,_, visceral_JJ leishmaniasis_NN (_( VLE_NP )_) ,_, toxoplasmosis_NN (_( TOX_NP )_) ,_, syphilis_NN (_( SYP_NP )_) ,_, borreliosis_NN (_( BOR_NP )_) ,_, human_JJ immunodeficiency_NN virus_NN (_( HIV_NP )_) ,_, cytomegalovirus_NN (_( CMV_NP )_) ,_, Epstein-Barr_NP virus_NN (_( EBV_NP )_) ,_, hepatitis_NP A_NP (_( HEA_NP )_) ,_, hepatitis_NP B_NP (_( HEB_NP )_) ,_, rubella_NN (_( RUB_NP )_) ,_, aspergillosis_NN (_( ASP_NP )_) ,_, rheumatoid_JJ factor_NN (_( RHF_NP )_) ,_, anti-nuclear_JJ factor_NN (_( ANA_NP )_) ,_, and_CC Coxsackie_NP B_NP virus_NN (_( COB_NP )_) and_CC in_IN sera_NN of_IN healthy_JJ Dutch_JJ blood_NN donors_NNS (_( HEC_NP )_) ._SENT TABLE_NN 1_CD |_SYM Sensitivity_NN and_CC specificity_NN of_IN the_DT WA/IHA_NP ,_, SEA/ELISA_NP ,_, and_CC the_DT combination_NN of_IN both_DT tests_NNS in_IN detecting_VBG schistosomiasis_JJ This_DT study_NN showed_VBD that_IN both_CC a_DT commercially_RB available_JJ IHA_NP test_NN using_VBG S._NP mansoni_NP adult_NN WA_NP and_CC an_DT ELISA_NP with_IN SEA_NP are_VBP sensitive_JJ and_CC specific_JJ tests_NNS for_IN the_DT serodiagnosis_NN of_IN schistosomiasis_NN in_IN travelers_NNS from_IN the_DT tropics_NNS ._SENT However_RB ,_, a_DT combination_NN of_IN these_DT tests_NNS is_VBZ recommended_VBN ,_, because_IN the_DT pooled_JJ results_NNS gave_VBD higher_JJR sensitivity_NN than_IN either_DT test_NN alone_RB while_IN maintaining_VBG high_JJ specificity_NN ._SENT IHA_NP tests_NNS using_VBG adult_JJ WA_NP have_VBP been_VBN evaluated_VBN previously_RB for_IN serodiagnosis_NN of_IN schistosomiasis_NN ._SENT All_DT but_CC one_CD of_IN these_DT IHA_NP tests_NNS were_VBD homemade_JJ systems_NNS that_WDT are_VBP not_RB readily_RB available_JJ for_IN use_NN outside_IN the_DT laboratories_NNS that_WDT developed_VBD them_PP (_( -_: ,_, ,_, )_) ,_, the_DT exception_NN being_VBG that_RB sold_VBN by_IN Dade_NP (_( Cellognost_NP ,_, Schistosomiasis_NP ;_: Behringwerke_NP AG_NP ,_, Marburg_NP ,_, Germany_NP )_) ._SENT In_IN these_DT IHA_NP tests_VBZ the_DT sensitivity_NN ranged_VBD from_IN 71_CD to_TO 80_CD %_NN and_CC the_DT specificity_NN ranged_VBD from_IN 80_CD to_TO 100_CD %_NN ._SENT The_DT IHA_NP test_NN that_WDT was_VBD produced_VBN by_IN Fumouze_NN until_IN 1996_CD used_VBN soluble_JJ egg_NN antigen_NN for_IN coating_NN of_IN the_DT erythrocytes_NNS instead_RB of_IN the_DT adult_JJ WA_NP as_IN in_IN the_DT test_NN kit_NN used_VBN for_IN the_DT present_JJ study_NN (_( personal_JJ communication_NN )_) ._SENT With_IN the_DT former_JJ IHA_NP test_NN a_DT sensitivity_NN of_IN 75.3_CD %_NN and_CC a_DT specificity_NN of_IN 96.9_CD %_NN was_VBD obtained_VBN ._SENT The_DT present_JJ IHA_NP test_NN of_IN Fumouze_NN (_( i.e._FW ,_, the_DT WA/IHA_NP that_WDT was_VBD used_VBN here_RB )_) has_VBZ not_RB been_VBN studied_VBN before_IN in_IN a_DT clinical_JJ setting_NN ._SENT Although_IN earlier_JJR studies_NNS suggested_VBD that_IN IHA_NP gave_VBD high_JJ specificity_NN ,_, these_DT studies_NNS incorporated_VBN only_RB a_DT few_JJ control_NN serum_NN samples_NNS ._SENT Because_IN schistosomiasis_NN is_VBZ often_RB observed_VBN in_IN conjunction_NN with_IN other_JJ infectious_JJ diseases_NNS and_CC autoimmune_JJ antibodies_NNS and_CC because_IN cross-reactive_JJ antibodies_NNS are_VBP frequently_RB observed_VBN with_IN other_JJ serological_JJ tests_NNS for_IN schistosomiasis_NN ,_, we_PP included_VBD a_DT large_JJ series_NN of_IN controls_NNS in_IN the_DT present_JJ study_NN ._SENT Taking_VBG the_DT size_NN and_CC variety_NN of_IN our_PP$ control_NN groups_NNS into_IN account_NN ,_, the_DT specificities_NNS observed_VBD with_IN the_DT WA/IHA_NP of_IN 98.9_CD and_CC 94.7_CD %_NN for_IN cutoff_NN titers_NNS of_IN 1:160_CD and_CC 1:80_CD ,_, respectively_RB ,_, were_VBD impressive_JJ ._SENT The_DT sensitivities_NNS of_IN the_DT WA/IHA_NP with_IN the_DT cutoff_NN titer_NN suggested_VBD by_IN the_DT manufacturer_NN (_( 1:160_CD )_) were_VBD relatively_RB low_JJ ._SENT For_IN diagnosis_NN of_IN imported_VBN schistosomiasis_NN a_DT high_JJ sensitivity_NN without_IN a_DT concomitant_JJ loss_NN of_IN specificity_NN is_VBZ ,_, however_RB ,_, generally_RB required_VBN ._SENT By_IN lowering_VBG the_DT cutoff_NN from_IN 1:160_CD to_TO 1:80_CD the_DT sensitivities_NNS of_IN the_DT WA/IHA_NP increased_VBD strongly_RB ,_, with_IN only_RB a_DT slight_JJ drop_NN in_IN specificity_NN ._SENT On_IN the_DT basis_NN of_IN these_DT observations_NNS we_PP suggest_VBP that_IN the_DT cutoff_NN titer_NN could_MD be_VB lowered_VBN to_TO 1:80_CD ._SENT It_PP is_VBZ in_IN any_DT case_NN questionable_JJ as_IN to_TO whether_IN all_DT 15_CD control_NN samples_NNS with_IN titers_NNS greater_JJR than_IN 1:80_CD were_VBD truly_RB false_JJ positives_NNS ._SENT Most_JJS of_IN these_DT patients_NNS had_VBD visited_VBN schistosoma-endemic_JJ countries_NNS ,_, and_CC although_IN parasitological_JJ examinations_NNS in_IN these_DT cases_NNS were_VBD negative_JJ ,_, coinfection_NN with_IN Schistosoma_NP spp._NP could_MD not_RB be_VB excluded_VBN ._SENT Because_IN severe_JJ symptomatology_NN is_VBZ observed_VBN in_IN some_DT cases_NNS of_IN Katayama_NP fever_NN ,_, accurate_JJ diagnosis_NN in_IN this_DT early_JJ stage_NN of_IN a_DT schistosoma_NN infection_NN is_VBZ important_JJ ._SENT Schistosoma_NP egg_NN production_NN in_IN patients_NNS with_IN Katayama_NP fever_NN is_VBZ often_RB just_RB commencing_VBG ,_, and_CC detection_NN of_IN eggs_NNS in_IN stool_NN or_CC urine_NN is_VBZ mostly_RB unsuccessful_JJ ._SENT Serodiagnosis_NN ,_, therefore_RB ,_, could_MD be_VB important_JJ ._SENT Our_PP$ findings_NNS suggested_VBD that_IN the_DT WA/IHA80_NP correctly_RB diagnosed_VBD 90.0_CD %_NN of_IN the_DT patients_NNS with_IN early_JJ infections_NNS associated_VBN with_IN Katayama_NP fever_NN ._SENT These_DT findings_NNS are_VBP in_IN contrast_NN to_TO those_DT of_IN two_CD earlier_JJR studies_NNS with_IN IHA_NP containing_VBG adult_JJ WA_NP ,_, a_DT homemade_JJ IHA_NP and_CC a_DT commercially_RB available_JJ IHA_NP (_( Dade_NP ,_, Cellgnost_NP ,_, Schistosomiasis_NP ,_, Behringwerke_NP AG_NP )_) ._SENT These_DT studies_NNS reported_VBD that_IN the_DT IHA_NP was_VBD insensitive_JJ for_IN detection_NN of_IN cases_NNS of_IN early_JJ schistosomiasis_NN associated_VBN with_IN Katayama_NP fever_NN ._SENT In_IN both_DT studies_NNS IHA_NP was_VBD compared_VBN with_IN an_DT indirect_JJ immunofluorescent_JJ test_NN (_( IFAT_NP )_) on_IN gut-associated_JJ antigens_NNS of_IN adult_JJ S._NP mansoni_NN worms_NNS which_WDT appeared_VBD more_RBR sensitive_JJ than_IN IHA_NP in_IN early_JJ schistosomiasis_NN ._SENT Although_IN the_DT precise_JJ composition_NN of_IN the_DT antigens_NNS used_VBN for_IN erythrocyte_NN coating_NN in_IN the_DT commercially_RB available_JJ WA/IHA_NP used_VBD in_IN our_PP$ study_NN is_VBZ unknown_JJ ,_, it_PP is_VBZ possible_JJ that_IN the_DT gut-associated_JJ antigens_NNS of_IN the_DT adult_NN worm_NN have_VBP been_VBN incorporated_VBN in_IN the_DT present_JJ IHA_NP coating_NN ._SENT The_DT negative_JJ IHA_NP results_NNS (_( 1:40_CD )_) for_IN one_CD of_IN the_DT Katayama_NP patients_NNS studied_VBN is_VBZ possibly_RB a_DT consequence_NN of_IN the_DT short_JJ period_NN between_IN infection_NN and_CC clinical_JJ presentation_NN ._SENT The_DT IFAT_NP also_RB has_VBZ a_DT window_NN period_NN of_IN approximately_RB 30_CD days_NNS after_IN infection_NN before_IN becoming_VBG positive_JJ ._SENT The_DT WA/IHA_NP titer_NN of_IN this_DT patient_NN rose_VBD to_TO 1:640_CD 3_CD months_NNS after_IN the_DT initial_JJ examination_NN ._SENT Because_IN of_IN this_DT delay_NN in_IN antibody_NN response_NN ,_, patients_NNS clinically_RB suspected_VBN of_IN having_VBG Katayama_NP fever_NN but_CC with_IN an_DT initially_RB negative_JJ serological_JJ test_NN result_NN should_MD be_VB reexamined_VBN serologically_RB a_DT few_JJ weeks_NNS later_RBR ._SENT The_DT data_NNS from_IN this_DT study_NN suggest_VBP that_IN the_DT WA/IHA_NP performs_VBZ slightly_RB better_JJR for_IN detection_NN of_IN S._NP mansoni_NP than_IN for_IN detection_NN of_IN S._NP haematobium_NN ._SENT This_DT result_NN agrees_VBZ with_IN those_DT of_IN others_NNS who_WP used_VBD IHA_NP tests_NNS with_IN adult_JJ WA_NP of_IN S._NP mansoni_NP ._SENT In_IN these_DT studies_NNS it_PP was_VBD demonstrated_VBN that_IN the_DT sensitivity_NN of_IN the_DT IHA_NP improved_VBN by_IN using_VBG homologous_JJ rather_RB than_IN heterologous_JJ antigens_NNS ._SENT To_TO overcome_VB the_DT relatively_RB limited_JJ sensitivity_NN of_IN the_DT WA/IHA_NP for_IN S._NP haematobium_NN infections_NNS the_DT antigen_NN composition_NN of_IN the_DT IHA_NP could_MD be_VB changed_VBN by_IN incorporating_VBG antigens_NNS of_IN S._NP haematobium_NN ._SENT ELISA_NP with_IN SEA_NP was_VBD evaluated_VBN in_IN this_DT study_NN as_IN well_RB ._SENT Because_IN large_JJ amounts_NNS of_IN SEA_NP are_VBP difficult_JJ to_TO obtain_VB ,_, we_PP developed_VBD a_DT more_RBR economic_JJ ELISA_NP method_NN with_IN microtiter_NN plates_NNS with_IN smaller_JJR wells_NNS than_IN the_DT standard_JJ plates_NNS (_( i.e._FW ,_, 30_CD mul_NN as_RB opposed_VBD to_TO 300_CD mul_NN )_) ._SENT In_IN this_DT form_NN our_PP$ ELISA_NN had_VBD a_DT sensitivity_NN of_IN 92.0_CD %_NN in_IN detecting_VBG egg-proven_NN cases_NNS of_IN imported_VBN schistosomiasis_NN ._SENT This_DT high_JJ sensitivity_NN agreed_VBN with_IN the_DT results_NNS of_IN several_JJ earlier_JJR studies_NNS carried_VBD out_RP with_IN standard_JJ microtiter_NN plates_NNS in_IN endemic_JJ and_CC nonendemic_JJ areas_NNS ,_, although_IN in_IN one_CD recent_JJ hospital_NN study_NN in_IN the_DT United_NP Kingdom_NP a_DT lower_JJR sensitivity_NN of_IN 72_CD %_NN was_VBD found_VBN ._SENT There_EX was_VBD no_DT difference_NN with_IN our_PP$ ELISA_NP in_IN detecting_VBG S._NP mansoni_NP and_CC S._NP haematobium_NN ,_, which_WDT confirmed_VBD the_DT results_NNS of_IN other_JJ studies_NNS ._SENT Although_IN the_DT ELISA_NP showed_VBD a_DT high_JJ sensitivity_NN in_IN detecting_VBG egg-proven_NN cases_NNS ,_, the_DT sensitivity_NN in_IN confirming_VBG clinical_JJ Katayama_NP fever_NN was_VBD low_JJ because_IN only_RB 5_CD of_IN the_DT 10_CD patients_NNS (_( 50_CD %_NN )_) showed_VBD positive_JJ reactions_NNS ._SENT In_IN this_DT context_NN it_PP has_VBZ previously_RB been_VBN noted_VBN that_IN ELISA_NP against_IN egg_NN antigen_NN is_VBZ unlikely_JJ to_TO detect_VB an_DT infection_NN in_IN which_WDT schistosoma_NN egg_NN production_NN has_VBZ just_RB started_VBN but_CC in_IN which_WDT anti-egg_NN antibody_NN synthesis_NN has_VBZ not_RB yet_RB commenced_VBN ._SENT In_IN this_DT stage_NN of_IN infection_NN signs_NNS and_CC symptoms_NNS of_IN Katayama_NP fever_NN are_VBP ,_, however_RB ,_, often_RB already_RB present_JJ ._SENT Thus_RB ,_, the_DT probability_NN that_IN cases_NNS of_IN Katayama_NP fever_NN can_MD be_VB confirmed_VBN by_IN ELISA_NP by_IN using_VBG egg_NN antigens_NNS is_VBZ relatively_RB low_JJ ._SENT Both_DT high_JJ and_CC low_JJ specificity_NN with_IN ELISA_NP have_VBP previously_RB been_VBN reported_VBN ._SENT Because_IN of_IN these_DT variable_JJ results_NNS specificity_NN in_IN the_DT present_JJ study_NN was_VBD determined_VBN by_IN using_VBG control_NN sera_NN ,_, including_VBG those_DT from_IN patients_NNS with_IN parasitic_JJ ,_, fungal_JJ ,_, bacterial_JJ ,_, and_CC viral_JJ infections_NNS ,_, as_RB well_RB as_IN from_IN people_NNS with_IN autoimmune_JJ antibodies_NNS ._SENT Despite_IN this_DT variety_NN of_IN control_NN groups_NNS the_DT specificity_NN of_IN the_DT SEA/ELISA_NP in_IN detecting_VBG schistosomiasis_NN was_VBD 98.2_CD %_NN ,_, which_WDT was_VBD considered_VBN excellent_JJ ._SENT Cross-reactivity_NN that_WDT was_VBD earlier_RBR observed_VBN with_IN ,_, e.g._FW ,_, filariasis_NN and_CC hepatitis_NN ,_, was_VBD not_RB observed_VBN in_IN our_PP$ study_NN ._SENT Our_PP$ results_NNS thus_RB suggest_VBP that_IN ELISA_NP carried_VBD out_RP on_IN plates_NNS containing_VBG small_JJ wells_NNS is_VBZ a_DT very_RB economic_JJ ,_, sensitive_JJ ,_, and_CC specific_JJ test_NN to_TO detect_VB schistosomiasis_NN after_IN the_DT onset_NN of_IN egg_NN production_NN ._SENT Although_IN this_DT study_NN suggests_VBZ that_IN WA/IHA_NP and_CC SEA/ELISA_NP are_VBP good_JJ diagnostic_JJ tools_NNS ,_, improvement_NN of_IN diagnosis_NN might_MD be_VB accomplished_VBN by_IN combining_VBG the_DT results_NNS of_IN the_DT two_CD tests_NNS ._SENT In_IN our_PP$ study_NN sensitivity_NN and_CC specificity_NN were_VBD determined_VBN after_IN combination_NN of_IN the_DT results_NNS of_IN either_CC the_DT WA/IHA80_NP or_CC the_DT WA/IHA160_NP with_IN those_DT of_IN the_DT SEA/ELISA_NP ._SENT It_PP showed_VBD that_IN these_DT combinations_NNS had_VBD the_DT highest_JJS sensitivities_NNS of_IN this_DT study_NN ._SENT Thus_RB ,_, the_DT combination_NN of_IN WA/IHA80_NP and_CC SEA/ELISA_NP detected_VBD 100_CD %_NN of_IN the_DT schistosomiasis_JJ cases_NNS and_CC 90_CD %_NN of_IN the_DT Katayama_NP cases_NNS and_CC had_VBD a_DT specificity_NN of_IN 92.9_CD %_NN ._SENT The_DT sensitivity_NN of_IN the_DT combination_NN of_IN WA/IHA160_NP and_CC SEA/ELISA_NP was_VBD lower_JJR but_CC still_RB gave_VBD 98.0_CD %_NN detection_NN of_IN egg-proven_NN cases_NNS and_CC 80_CD %_NN confirmation_NN of_IN Katayama_NP fever_NN with_IN a_DT specificity_NN of_IN 97.2_CD %_NN ._SENT Combining_VBG the_DT results_NNS of_IN both_DT WA/IHA_NP and_CC SEA/ELISA_NP thus_RB improved_VBD the_DT sensitivity_NN with_IN maintenance_NN of_IN high_JJ specificity_NN ._SENT In_IN an_DT earlier_JJR study_NN a_DT combination_NN of_IN both_DT IFAT_NP and_CC ELISA_NP has_VBZ also_RB been_VBN claimed_VBN to_TO give_VB a_DT higher_JJR reliability_NN in_IN diagnosis_NN of_IN schistosomiasis_NN ,_, but_CC the_DT sensitivity_NN and_CC specificity_NN of_IN this_DT combination_NN were_VBD not_RB reported_VBN ._SENT In_IN conclusion_NN ,_, we_PP suggest_VBP that_IN a_DT commercially_RB available_JJ IHA_NP is_VBZ a_DT good_JJ diagnostic_JJ tool_NN for_IN detection_NN of_IN imported_VBN schistosomiasis_NN ._SENT The_DT test_NN is_VBZ easily_RB applicable_JJ and_CC specific_JJ ._SENT Both_DT infections_NNS with_IN S._NP mansoni_NP and_CC S._NP haematobium_NN can_MD be_VB diagnosed_VBN ,_, and_CC the_DT test_NN is_VBZ sensitive_JJ for_IN confirmation_NN of_IN Katayama_NP fever_NN ._SENT Our_PP$ SEA/ELISA_NN is_VBZ also_RB an_DT economic_JJ ,_, sensitive_JJ ,_, and_CC specific_JJ test_NN for_IN detection_NN of_IN schistosomiasis_NN after_IN the_DT onset_NN of_IN egg_NN production_NN ._SENT Pooling_VBG the_DT results_NNS of_IN both_CC the_DT WA/IHA_NP and_CC the_DT SEA/ELISA_NP gave_VBD the_DT most_RBS reliable_JJ outcome_NN because_IN it_PP increased_VBD considerably_RB the_DT sensitivity_NN in_IN all_DT stages_NNS of_IN infection_NN with_IN maintenance_NN of_IN high_JJ specificity_NN ,_, particularly_RB when_WRB the_DT results_NNS of_IN the_DT WA/IHA160_NP were_VBD used_VBN in_IN the_DT combination_NN with_IN those_DT of_IN the_DT SEA/ELISA_NP ._SENT 